67367-24-2 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 4-hydroxynicotinate is used as a reagent for the synthesis of Trigonelline (T794000), an alkaloid with potential applications in the development of pharmaceutical products due to its phytoestrogenic activity. This activity may contribute to the regulation of hormonal balance and could be beneficial in the treatment of conditions related to hormonal imbalances.
Used in Chemical Synthesis:
As a white powder chemical compound, Methyl 4-hydroxynicotinate is also utilized in various chemical synthesis processes, where it can act as an intermediate or a building block for the creation of other complex molecules with diverse applications in different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 67367-24-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,3,6 and 7 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 67367-24:
(7*6)+(6*7)+(5*3)+(4*6)+(3*7)+(2*2)+(1*4)=152
152 % 10 = 2
So 67367-24-2 is a valid CAS Registry Number.
InChI:InChI=1/C7H7NO3/c1-11-7(10)5-4-8-3-2-6(5)9/h2-4H,1H3,(H,8,9)
67367-24-2Relevant articles and documents
Monoacylglycerol Lipase Modulators
-
Paragraph 0410; 0624, (2020/04/24)
Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R2, R3 R4, R5 and R6 are defined herein.
MODIFIED COMPOUND OF ANDROGRAPHOLIDE
-
Paragraph 0214-0216, (2019/01/04)
The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.
